MUSTANG BIO, INC.
Close on Oct 19, 2026
- Market cap
- $2.51M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2024 Ended Mar 31, 2024 | Apr 29, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 11, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | After market close | – | $-1.23 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | After market close | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 12, 2023 | After market close | – | $-2.06 | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 29, 2023 | After market close | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 14, 2022 | After market close | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 11, 2022 | After market close | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 12, 2022 | After market close | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 23, 2022 | After market close | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Nov 12, 2021 | Before market open | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Aug 16, 2021 | After market close | – | – | – |
Press releases
Announcements Mustang Bio filed with the SEC
Mustang Bio Granted Orphan Drug Designation
Other events · EX-99.1 to Form 8-K
Mustang Bio Regains Compliance with Nasdaq
Other events · EX-99.1 to Form 8-K
Mustang Bio Announces Sale of Fixed Assets and
Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
Bio Announces Pricing of $8 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Mustang Bio Announces Closing of $8 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Mustang Bio Regains Compliance with Nasdaq
Material agreement · Other events · EX-99.3 to Form 8-K
Mustang Bio Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Mustang Bio Announces Exercise of Warrants for $4 Million
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Mustang Bio Announces $2.5 Million Registered
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Mustang Bio Announces Closing of $2.5 Million
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Mustang Bio Announces Pricing of $4 Million
Material agreement · Other events · EX-99.1 to Form 8-K
Mustang Bio Announces Closing of $4 Million
Material agreement · Other events · EX-99.2 to Form 8-K
Full-Year 2023 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of
Other events · EX-99.1 to Form 8-K
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Mustang Bio Announces $4.4 Million Registered Direct Offering Priced
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Mustang Bio Announces Closing of $4.4 Million
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR T Cell Therapy
Other events · EX-99.1 to Form 8-K
Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates
Material agreement · Agreement terminated · Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Mustang Bio Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Full-Year 2021 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K